Tuesday, May 14, 2024
5/14/2024
DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is a progressive and ultimately fatal neurodegenerative disease that affects more than five million people in the USA. Currently there is no cure for AD. Available medicines are aimed only at temporarily reducing symptoms and slowing down the progression of the disease. While many new compounds have been developed to treat AD, they have not been successful in clinical studies and consequently there is a great need for development of new therapeutic strategies. Recent data show that retinoic acid (RA) plays an important role in maintaining neuronal plasticity, and learning and memory in human or in transgenic animal model of AD, and support our hypothesis that increasing RA in the brain will improve AD patient outcomes. However, RA has poor pharmacokinetics in humans and it induces its own clearance resulting in loss of activity during long-term use. In this STTR effort, Dermaxon will use inhibition of RA clearance, instead of treatment with RA itself as a novel therapeutic strategy to treat or prevent progression of cognitive impairments associated with AD. The clearance of RA is predominantly mediated by cytochrome P450 family 26 enzymes (CYP26) of which there are three isoforms: CYP26A1, CYP26B1 and CYP26C1. While CYP26A1 appears to be the human liver RA hydroxylase, CYP26B1 is predicted to be responsible for RA metabolism in extrahepatic tissues and CYP26C1 appears to prefer 9cis-RA as a substrate. In preliminary studies, different chemotypes with a nanomolar IC50 at CYP26A1 and/or CYP26B1 have been identified. Such a novel class of compounds is expected to be highly specific for the different CYP26 isoforms, thereby avoiding side effects and non-target P450 inhibition associated with previously described CYP26 inhibitors. Dermaxon's goal is to develop the next generation of novel selective inhibitors of CYP26, to increase RA concentration in the brain, and to treat memory impairment associated with AD. Using our previously discovered lead structures, we will first generate a series of new compounds with improved CYP26 inhibition potency and selectivity. We will then evaluate their pharmacokinetic properties in mice as well as their efficacy in rescuing memory deficits in the AD mouse model PS1-APP. By the end of this Phase I STTR, Dermaxon will have identified a candidate compound that selectively targets CYP26B1 and also provide evidence that these compounds exhibit in vivo efficacy in rescuing the memory deficit in AD mouse model. In the Phase II of this STTR project we will initiate FDA discussions and complete pre-clinical studies required to file an Investigational New Drug Application (IND) to initiate clinical studies.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
